uniQure N.V. Foreign Currency Transaction Loss, before Tax
uniQure N.V. (QURE) reported Foreign Currency Transaction Loss, before Tax of $200.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ForeignCurrencyTransactionLossBeforeTax · last filed 2018-11-06
- uniQure N.V. foreign currency transaction loss, before tax for the quarter ending 2018-09-30 was $200.00K.
- uniQure N.V. foreign currency transaction loss, before tax for the quarter ending 2018-06-30 was $1.10M.
- uniQure N.V. foreign currency transaction loss, before tax for the quarter ending 2016-09-30 was $200.00K.
| Period end | Foreign Currency Transaction Loss, before Tax 3 month | Foreign Currency Transaction Loss, before Tax 6 month | Foreign Currency Transaction Loss, before Tax 9 month |
|---|---|---|---|
| 2018-09-30 | $200.00K 10-Q · filed 2018-11-06 | $1.30M derived: sum of 2 quarters · filed 2018-11-06 | $700.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.10M 10-Q · filed 2018-08-08 | $600.00K 10-Q · filed 2018-08-08 | |
| 2016-09-30 | $200.00K 10-Q · filed 2017-11-01 | $400.00K 10-Q · filed 2017-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |